Skip to main content

Table 1 Baseline characteristics of the participants

From: Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study

Characteristics

n=24

Age, years (median, IQR)

45.5 (41.0–54.0)

Male, %

58.3

CD4+ T cell count, cells/mm3 (median, IQR)

661.5 (559.3–827.0)

Undetectable HIV viral load, %

95.8

Duration of ATV/r use, months (median, IQR)

36 (24–48)

Comorbidities, %

  None

50.0

  Dyslipidemia

25.0

  Chronic HBV or HCV

16.7

Cardiovascular risk factors*, %

  <2

74.0

  ≥2

25.0

10-year CVD risk, % (median, IQR)

2.7 (1.9–5.4)

Baseline lipid profiles, mg/dL (median, IQR)

  Total cholesterol

242.5 (215.0–264.0)

  LDL-cholesterol

144 (127.0–160.0)

  HDL-cholesterol

41.0 (34.0–46.0)

  Triglyceride

190.0 (145.0–355.0)

  1. *Current smoking, systolic blood pressure ≥140 mmHg or on antihypertensive drugs, HDL-cholesterol <40 mg/dL, premature coronary heart disease in first-degree relative (age <55 years in male and <65 years in female), and age >45 years in male or >55 years in female
  2. ATV/r atazanavir/ritonavir, CVD cardiovascular risk, HBV hepatitis B virus, HCV hepatitis C virus, HDL high-density lipoprotein, IQR interquartile range, LDL low-density lipoprotein